Physical therapy management of Pompe disease

Genetics in Medicine

Volumn 8, Issue 5, 2006, Pages 318-327

  Case, Laura Elizabeth ^a   Kishnani, Priya Sunil ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acid maltase deficiency; Glycogen storage disease; Lysosomal storage disease; Physical therapy; Pompe

Indexed keywords

GLUCAN 1,4 ALPHA GLUCOSIDASE; GLYCOGEN;

AUTOSOMAL RECESSIVE DISORDER; BODY POSITION; CLINICAL FEATURE; DEATH; DISEASE COURSE; DISEASE SEVERITY; ENZYME REPLACEMENT; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; KINESIOLOGY; LYSOSOME; MOTOR PERFORMANCE; MUSCLE CONTRACTURE; MUSCLE STRENGTH; MUSCLE WEAKNESS; OSTEOPENIA; OSTEOPOROSIS; PHYSICAL CAPACITY; PHYSIOTHERAPY; RESPIRATORY FUNCTION; REVIEW; SITTING; SKELETAL MUSCLE; SURVIVAL; SYMPTOM; WALKING; INFANT; MUSCULOSKELETAL SYSTEM MALFORMATION; PATHOPHYSIOLOGY; STANDARD;

GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INFANT; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MUSCULOSKELETAL ABNORMALITIES; PHYSICAL THERAPY MODALITIES;

EID: 33745625409     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gim.0000217789.14470.c5     Document Type: Review

References (60)

1. Hirschhorn Reuser AJJ. Glycogen storage disease type II: acid alphα-glucosidase (acid maltase) deficiency. In: Scriver ABC, Sly W, et al. (eds.). The Metabolic and Molecular Bases of Metabolic Disease. New York: McGraw Hill;2001:3389-3420.
2. Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr 2004;.144:S35-S43.
3. Laforet P, Nicolino M, Eymard PB, Pucch JP, et al. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation Neurology 2000;55:1122-1128.
4. Swash M, Schwartz MS, Apps MC. Adult onset acid maltase deficiency. Distribution and progression of clinical and pathological abnormality in a family. J Neurol Sci 1985;68:61-74.
5. Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alphα-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001;3:132-138.
6. Van den Hout JM, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human alphα-glucosidase from milk. Pediatrics 2004;113:448-457.
7. Winkel LP, Van den Hout JM, Kamphoven JH, et al. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol 2004;55:495-502.
8. Kishnani PV, Nicolino T, Tsai M, Herman CH, et al. Enzyme replacement therapy with recombinant Human Acid alpha glucosidase (rhGAA) in InfantilePompe Disease (IPD): results from a Phase 2 study. Pediatric Research 2003;53:A259.
9. Klinge L, Straub V, Neudorf U, Schaper J, et al. Safety and efficacy of recombinant acid alphα-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 2005;15:24-31.
10. Klinge L, Straub V, Neudorf U, Voit T. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study. Neuropediatrics 2005;36:6-11.
11. Griffin JL. Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture. Virchows Arch B Cell Pathol Incl Mol Pathol 1984;45:23-36.
12. Hesselink RP, Wagenmakers AJ, Drost MR, Van der Vusse GJ. Lysosomal dysfunction in muscle with special reference to glycogen storage disease type II. Biochim Biophys Acta 2003;1637:164-170.
13. Griffin JL. Infantile acid maltase deficiency. II. Muscle fiber hypertrophy and the ultrastructure of end-stage fibers. Virchows Arch B Cell Pathol Incl Mol Pathol 1984;45:37-50.
14. Chan WP, Liu GC. MR imaging of primary skeletal muscle diseases in children. AJR Am J Roentgenol 2002;179:989-997.
15. Bembi B, Ciana G, Martini C, Benettoni A, et al. Efficacy of multidisciplinary approach in the treatment of two cases of nonclassical infantile glycogenosis type II. J Inherit Metab Dis 2003;26:675-681.
16. Umpleby AM, Wiles CM, Trend PS, Scobie IN, et al. Protein turnover in acid maltase deficiency before and after treatment with a high protein diet. J Neurol Neurosurg Psychiatry 1987;50:587-592.
17. Umpleby AM, Trend PS, Chubb D, Conaglen JV, et al. The effect of a high protein diet on leucine and alanine turnover in acid maltase deficiency. J Neurol Neurosurg Psychiatry. Aug 1989;52:954-961.
18. Slonim AE, Coleman RA, McElligot MA, Najjar J, et al. Improvement of muscle function in acid maltase deficiency by high-protein therapy. Neurology 1983;33:34-38.
19. Hesselink RP, Gorselink M, Schaart G, Wagenmakers AJ, et al. Impaired performance of skeletal muscle in alpha-glucosidase knockout mice. Muscle Nerve 2002;25:873-883.
20. Drost MR, Hesselink RP, Oomens CW, van der Vusse GJ. Effects of non-contractile inclusions on mechanical performance of skeletal muscle. J Biomech 2005;38:1035-1043.
21. Lewis SF, Haller RG. Skeletal muscle disorders and associated factors that limit exercise performance. Exerc Sport Sci Rev 1989;17:67-113.
22. Perez A, Mulot R, Vardon G, Barois A, et al. Thoracoabdominal pattern of breathing in neuromuscular disorders. Chest 1996;110:454-461.
23. Felice KJ, Alessi AG, Grunnet ML. Clinical variability in adult-onset acid maltase deficiency: report of affected sibs and review of the literature. Medicine 1995;74:131-135.
24. Hagemans ML, Winkel LP, Van Doorn PA, Hop WJ, et al. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 2005;128:671-677.
25. Pichiecchio A, Uggetti C, Ravaglia S, Egitto MG, et al. Muscle MRI in adult-onset acid maltase deficiency. Neuromuscul Disord 2004;14:51-55.
26. de Jager AE, van der Vliet TM, van der Ree TC, Oosterink BJ, et al. Muscle computed tomography in adult-onset acid maltase deficiency. Muscle Nerve 1998;21:398-400.
27. Cinnamon J, Slonim AE, Black KS, Gorey MT et al. Evaluation of the lumbar spine in patients with glycogen storage disease: CT demonstration of patterns of paraspinal muscle atrophy. AJNR Am J Neuroradiol 1991;12:1099-1103.
28. Fowler WM. Rehabilitation management of muscular dystrophy and related disorders: II. Comprehensive care. Arch Phys Med Rehabil 1982;63:322-328.
29. Roy L, Gibson DA. Pseudohypertrophic muscular dystrophy and its surgical management: review of 30 patients. Can J Surg 1970;13:13-21.
30. Ausems MG, Wokke JH, Reuser AJ, van Diggelen OP. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 2001;57:1938.
31. Sutherland DH, Olshen R, Cooper L et al. The pathomechanics of gait in Duchenne muscular dystrophy. Dev Med Child Neurol 1981;23:3-22.
32. Iannaccone ST, Russman BS, Browne RH, Buncher CR et al. Prospective analysis of strength in spinal muscular atrophy. DCN/Spinal Muscular Atrophy Group. J Child Neurol 2000;15:97-101.
33. Vignos PJ Jr. Physical models of rehabilitation in neuromuscular disease. Muscle Nerve 1983;6:323-338.
34. Fowler WM. Role of physical activity and exercise training in neuromuscular diseases. Am J Phys Med Rehabil 2002;81:S187-S195.
35. LeVeau BF, Bernhardt DB. Developmental biomechanics. Effect of forces on the growth, development, and maintenance of the human body. Phys Ther 1984;64:1874-1882.
36. Tardieu C, Lespargot A, Tabary C, Bret MD. For how long must the soleus muscle be stretched each day to prevent contracture? Dev Med Child Neurol 1988;30:3-10.
37. Archibald KC, Vignos Jr. PJ. A study of contractures in muscular dystrophy. Arch Phys Med Rehabil 1959;40:150-157.
38. Baker JH, Matsumoto DE. Adaptation of skeletal muscle to immobilization in a shortened position. Muscle Nerve 1988;11:231-244.
39. Kendall FPaM EK. Muscles-Testing and Function. Baltimore: Williams & Wilkins; 1983.
40. Garcia-Cabezas MA, Garcia-Alix A, Martin Y, Gutierrez M, et al. Neonatal spinal muscular atrophy with multiple contractures, bone fractures, respiratory insufficiency and 5q13 deletion. Acta Neuropathol (Berl) 2004;107:475-478.
41. Krishnamurthy V, Hanna R, Mackey JM, Dearmy S, et al. Osteopenia in Pompe Disease: A Case Series Presentation. Paper presented at: Society of Inherited Metabolic Disorders; May 2005, 2005; Monterey, CA.
42. Oktenli C. Renal magnesium wasting, hypomagnesemic hypocalcemia, hypocalciuria and osteopenia in a patient with glycogenosis type II. Am J Nephrol 2000; 20:412-417.
43. Kishnani PS, Hwu P, Mandel H, Nicolino M, et al. On behalf of the Infantile-onset Pompe Disease Natural History Study Group-A retrospective, multinational, multicenter study of the natural history of infantile-onset Pompe disease. J Pediatrics (in press).
44. van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003;112:332-340.
45. Haley SM, Fragala MA, Skrinar AM. Pompe disease and physical disability. Dev Med Child Neurol 2003;45:618-623.
46. Haley SM. The emerging role of the pediatric physical therapist in evaluation and intervention for individuals with lysosomal storage diseases. Ped Phys Ther 2005;17:128-139.
47. International Classification of Functioning, Disability, and Health (ICF). World Health Organization - 2001. Available at http://www.who.int/ classifications/icf/en/. Accessed April 6, 2006.
48. Guide to Physical Therapy Practice. Physical Therapy 2001;81.
49. Slonim AE, Bulone L, Minikes J, Hays AP, et al. Benign course of glycogen storage disease type IIb in two brothers: Nature or nurture? Muscle Nerve 2006;33:571-574.
50. Slonim A, Rosenthal H, O'Connor MR, Goldberg T et al. High protein and exercise therapy (HPET) for childhood acid maltase deficiency (AMD). J Neurolog Sci 1990;98:465.
51. Raben N, Fukuda T, Gilbert AL, de Jong D, et al. Replacing acid alphα-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther 2005;11:48-56.
52. Figuers C. Aquatic therapy intervention for a child diagnosed with spinal muscular atrophy. Physical Therapy Case Reports 1999;2:109-112.
53. Finder JD, Birnkrant D, Carl J, Farber HJ, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med 2004;170:456-465.
54. Wagener JS, Headley AA. Cystic fibrosis: current trends in respiratory care. Respir Care 2003;48:234-246.
55. McDonald CM. Limb contractures in progressive neuromuscular disease and the role of stretching, orthotics, and surgery. Phys Med Rehabil Clin N Am 1998;9:187-211.
56. Hyde SA, FlLytrup I, Glent S, Kroksmark AK, et al. A randomized comparative study of two methods for controlling Tendo Achilles contracture in Duchenne muscular dystrophy. Neuromuscul Disord 2000;10:257-263.
57. Ward K, Alsop C, Caulton J, Rubin C, et al. Low magnitude mechanical loading is osteogenic in children with disabling conditions. J Bone Miner Res 2004;19:360-369.
58. Biggar WD, Bachrach LK, Henderson RC, Kalkwarf H, et al. Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscul Disord 2005;15:80-85.
59. Stuberg WA. Muscular dystrophy and spinal muscular atrophy. In: Campbell SK, Vander Linden DW, Palisano RJ, ed. Physical Therapy for Children. second ed. Philadelphia: W. B. Saunders Company; 2000:339-368.
60. Jones MA, McEwen IR, Hansen L. Use of power mobility for a young child with spinal muscular atrophy. Phys Ther 2003;83:253-262.